Advertisement
Written by the OrganizedWisdom Team with as the reviewer. All original content is supervised by the The OrganizedWisdom Medical Review Team
esciencenews.com
1 of 0
Combining the new drug trabectedin with pegylated liposomal doxorubicin provides clinical benefit to women with relapsed ovarian cancer, according to new results presented at the 33rd Congress of the European Society for Medical Oncology (ESMO) in Stockholm.
Advertisement
This site complies with the HONcode standard for trustworthy health information: verify here.
© 2012 OrganizedWisdom.com, Inc. All rights reserved.
OrganizedWisdom does not provide medical advice, diagnosis or treatment. If you think you
may have a medical emergency, call your doctor or 911 immediately.
As Seen In
